Please login to the form below

Not currently logged in
Email:
Password:

TMC435

This page shows the latest TMC435 news and features for those working in and with pharma, biotech and healthcare.

Janssen buys hepatitis C candidate from GSK

Janssen buys hepatitis C candidate from GSK

The company plans to start trials combining GSK2336805 with its non-nucleoside polymerase inhibitor TMC647055 and simeprevir (TMC435) - an NS3/4A protease inhibitor developed with Sweden's Medivir.

Latest news

  • BMS and Vertex partner on oral hepatitis treatment BMS and Vertex partner on oral hepatitis treatment

    BMS' daclatasvir is an NS5A replication complex inhibitor that is already under investigation in combination with several other therapies, including Tibotec's NS3 protease inhibitor simeprevir (formerly known as TMC435) and

  • Merck and Roche team up for hepatitis C studies

    BMS 650032, and Johnson &Johnson/Tibotec's TMC435, all of which are in phase III testing.

  • BMS and Tibotec plan all-oral hepatitis C regimen

    The therapy would combine BMS' daclatasvir (BMS-790052), an NS5A replication complex inhibitor, with Tibotec's NS3 protease inhibitor TMC435, which is partnered with Medivir. ... Tibotec is currently conducting two phase II trials for TMC435 in

  • Medivir buys BioPhausia

    Medivir says that the acquisition would provide it with a well-established commercial platform from which to launch its hepatitis C drug TMC435, which should be introduced on to the market ... of TMC435.”.

More from news
Approximately 0 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....